Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

The Lancet Oncology

Volumn 18, Issue 3, 2017, Pages 393-403

  Coens, Corneel ^a   Suciu, Stefan ^a   Chiarion Sileni, Vanna ^b   Grob, Jean Jacques ^c   Dummer, Reinhard ^d   Wolchok, Jedd D ^e   Schmidt, Henrik ^f   Hamid, Omid ^g   Robert, Caroline ^h   Ascierto, Paolo A ⁱ   Richards, Jon M ^j   Lebbé, Celeste ^k   Ferraresi, Virginia ^l   Smylie, Michael ^m   Weber, Jeffrey S ⁿ   Maio, Michele ^o   Bottomley, Andrew ^a   Kotapati, Srividya ^p   de Pril, Veerle ^p   Testori, Alessandro ^q   Eggermont, Alexander M M ^h   more..

^a EORTC DATA CENTER   (Belgium)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c TIMONE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g Angeles Clinic and Research Institute   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j Oncology Specialists   (United States)

^k Assistance Publique des Hôpitaux de Paris AP HP   (United Kingdom)

^l Istituti Fisioterapici Ospitalieri Rome   (Italy)

^m CROSS CANCER INSTITUTE   (Canada)

ⁿ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^o UNIVERSITY HOSPITAL OF SIENA   (Italy)

^p BRISTOL MYERS SQUIBB   (United States)

^q EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PLACEBO; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EORTC QLQ C30; FATIGUE; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; INSOMNIA; LONGITUDINAL STUDY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; INTERNATIONAL COOPERATION; MELANOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; YOUNG ADULT;

EID: 85011277323     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30015-3     Document Type: Article

References (29)

1. 1 Eggermont, A, Spatz, A, Robert, C, Cutaneous melanoma. Lancet 383 (2014), 816–827.
2. 2 Balch, CM, Gershenwald, JE, Soong, S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
3. 3 Balch, CM, Gershenwald, JE, Soong, S-J, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
4. 4 van der Ploeg, AP, van Akkooi, AC, Rutkowski, P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29 (2011), 2206–2214.
5. 5 van der Ploeg, AP, van Akkooi, AC, Haydu, LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 50 (2014), 111–120.
6. 6 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
7. 7 Robert, C, Thomas, L, Bondarenko, I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
8. 8 Eggermont, AM, Chiarion-Sileni, V, Grob, JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
9. 9 Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
10. 10 De Wolf, L, Koller, M, Velikova, G, et al. EORTC translating procedures, 2009, EORTC Publications, Brussels.
11. 11 Fayers, P, Aaronson, N, Bjordal, K, et al. EORTC QLQ-C30 Scoring Manual, 3rd edn., 2001, EORTC Publications, Brussels.
12. 12 Young, T, de Haes, H, Fayers, P, et al. Guidelines for assessing quality of life in clinical trials, 1999, EORTC Quality of Life Study Group Publications, Brussels.
13. 13 Osoba, D, Rodrigues, G, Myles, J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998), 139–144.
14. 14 King, MT, The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5 (1996), 555–567.
15. 15 Matthews, JNS, Altman, DG, Campbell, MJ, Royston, P, Analysis of serial measurements in medical research. BMJ 300 (1990), 230–235.
16. 16 Fairclough, DL, Design and analysis of quality of life studies in clinical trials, 2002, Chapman & Hall/CRC, Boca Raton.
17. 17 Fayers, P, Hays, R, Assessing quality of life in clinical trials: methods and practice, 2005, Oxford University Press, New York.
18. 18 Young, T, de Haes, H, Curran, D, et al., on behalf of the EORTC Quality of Life Group. EORTC manual, 2002, EORTC, Brussels.
19. 19 Efficace, F, Bottomley, A, Osoba, D, et al. Beyond the development of health-related quality of life (HRQoL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQoL evaluation in prostate cancer research inform clinical decision making. J Clin Oncol 21 (2003), 3502–3511.
20. 20 Calvert, M, Blazeby, J, Altman, DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309 (2013), 814–822.
21. 21 Lebbé, C, Weber, JS, Maio, M, et al. Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25 (2014), 2277–2284.
22. 22 Horvat, TZ, Adel, NG, Dang, T, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33 (2015), 3193–3198.
23. 23 Wolchok, JD, Neyns, B, Linette, G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
24. 24 Weber, JS, Dummer, R, de Pril, V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119 (2013), 1675–1682.
25. 25 Revicki, DA, van den Eertwegh, AJ, Lorigan, P, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 10 (2012), 66–73.
26. 26 Johnson, DB, Friedman, DL, Berry, E, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res 3 (2015), 464–469.
27. 27 Bottomley, A, Aaronson, NK, European Organisation for Research and Treatment of Cancer. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol 25 (2007), 5082–5086.
28. 28 Cocks, K, King, MT, Velikova, G, Martyn St-James, M, Fayers, PM, Brown, JM, Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29 (2011), 89–96.
29. 29 Bottomley, A, Coens, C, Suciu, S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27 (2009), 2916–2923.